Tara Braithwaite
Family Medicine · Washington, PANPI 1386137966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $822, more than ten times the $16 reported in 2020.
Across 90 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$403
- Pfizer$253
- Novo Nordisk$173
- GSK$165
- Lilly USA, LLC$112
- Medtronic$104
- plus $640 from 17 others
What the payments were for
- Food & beverage$1,850100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $403 |
| Pfizer | 14 | $253 |
| Novo Nordisk | 9 | $173 |
| GSK | 9 | $165 |
| Lilly USA, LLC | 6 | $112 |
| Medtronic | 4 | $104 |
| Merck | 5 | $100 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $88 |
| Organon | 6 | $84 |
| Sanofi Pasteur Inc. | 2 | $60 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| AstraZeneca | 1 | $28 |
| Tonix Medicines, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Biogen | 1 | $22 |
| Linus Health, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Verrica Pharmaceuticals Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$125
How this compares
$1,850 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $33,287 |
| OzempicSemaglutide | 25 | $25,513 |
| TrulicityDulaglutide | 21 | $21,175 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $19,985 |
| EliquisApixaban | 11 | $6,325 |
| DuleraMometasone/Formoterol | 13 | $4,080 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,258 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,590 |
| Icosapent Ethyl | 12 | $1,412 |
| Rosuvastatin Calcium | 90 | $1,410 |
| Gabapentin | 79 | $1,170 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,004 |
| Levothyroxine Sodium | 81 | $888 |
| Duloxetine Hcl | 46 | $714 |
| Lisinopril | 97 | $713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $173 | $25,51325 claims |
| Lilly USA, LLCTrulicity | $112 | $21,17521 claims |
| GSKTrelegy Ellipta | $165 | $19,98524 claims |
| PfizerEliquis | $253 | $6,32511 claims |
| MerckDulera | $100 | $4,08013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Washington
- Daniel HoltWashington$30K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.